Accolade Management

How has Raj Singh's remuneration changed compared to Accolade's earnings?
Date	Total Comp.	Salary	Company Earnings
May 31 2023	n/a	n/a	-US$155m
Feb 28 2023	US$2m	US$500k	-US$460m
Nov 30 2022	n/a	n/a	-US$464m
Aug 31 2022	n/a	n/a	-US$401m
May 31 2022	n/a	n/a	-US$417m
Feb 28 2022	US$6m	US$471k	-US$123m
Nov 30 2021	n/a	n/a	-US$93m
Aug 31 2021	n/a	n/a	-US$132m
May 31 2021	n/a	n/a	-US$85m
Feb 28 2021	US$3m	US$400k	-US$51m
Nov 30 2020	n/a	n/a	-US$48m
Aug 31 2020	n/a	n/a	-US$50m
May 31 2020	n/a	n/a	-US$49m
Feb 29 2020	US$3m	US$394k	-US$51m
Nov 30 2019	n/a	n/a	-US$56m
Feb 28 2019	US$574k	US$350k	-US$56m

Compensation vs Market: Raj's total compensation ($USD2.00M) is below average for companies of similar size in the US market ($USD3.52M).

Compensation vs Earnings: Raj's compensation has been consistent with company performance over the past year.

CEO

Raj Singh (55 yo)

8yrs

Tenure

US$1,998,407

Compensation

Mr. Rajeev Singh, also known as Raj, serves as Director at Amperity, Inc. He has been the Chief Executive Officer and Executive Director of Accolade, Inc. since October 2015 and also serves as its Chairman...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Rajeev Singh	Chairman of the Board & CEO	8yrs	US$2.00m	0.78% $ 6.1m
Robert Cavanaugh	President	4.8yrs	US$1.13m	0.22% $ 1.7m
Stephen Barnes	CFO & Treasurer	8.7yrs	US$1.14m	0.19% $ 1.5m
Kristen Bruzek	Senior Vice President of Operations	less than a year	no data	no data
Colin McHugh	Chief Accounting Officer	less than a year	no data	0.041% $ 326.6k
Todd Friedman	Senior Vice President of Investor Relations	3yrs	no data	no data
Richard Eskew	Executive VP	5.5yrs	no data	0.042% $ 330.8k
Jennifer Hanson	Executive VP & Chief Human Resource Officer	1.4yrs	no data	no data
Drew Garner	Executive Vice President of Engineering	1.8yrs	no data	no data
Shantanu Nundy	Executive VP of Care Delivery	3.8yrs	no data	no data
James Wantuck	Senior VP & Associate Chief Medical Officer	less than a year	no data	no data
Ryan McQuaid	Executive Vice President of Product & Member Marketing	2.2yrs	no data	no data

2.6yrs

Average Tenure

51yo

Average Age

Experienced Management: ACCD's management team is considered experienced (2.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Rajeev Singh	Chairman of the Board & CEO	8yrs	US$2.00m	0.78% $ 6.1m
Shantanu Nundy	Executive VP of Care Delivery	4.8yrs	no data	no data
Dawn Lepore	Independent Director	4.3yrs	US$237.00k	0% $ 0
Jeffrey Jordan	Independent Director	7.3yrs	US$222.00k	0.025% $ 194.3k
Michael Hilton	Director	less than a year	US$706.70k	0.45% $ 3.5m
Patricia Wadors	Independent Director	3.7yrs	US$222.00k	0.025% $ 194.3k
Peter Klein	Lead Independent Director	4.1yrs	US$262.00k	0.025% $ 200.3k
Larry Kaiser	Member of Medical Advisory Board	no data	no data	no data
Jeffrey Brodsky	Independent Director	2.3yrs	US$222.00k	0.034% $ 265.9k
Joseph Betancourt	Member of Medical Advisory Board	no data	no data	no data
Saul Weiner	Member of Medical Advisory Board	no data	no data	no data
Jennifer Lerner	Member of Medical Advisory Board	no data	no data	no data

4.2yrs

Average Tenure

58yo

Average Age

Experienced Board: ACCD's board of directors are considered experienced (4.2 years average tenure).

Accolade Management

Management criteria checks 4/4

Key information

Recent management updates

Accolade Expands Physician-Executive Leadership to Enhance Care Delivery and Improve the Healthcare Experience

Accolade, Inc., Annual General Meeting, Aug 08, 2023

Chairman of the Board & CEO exercised options to buy US$4.3m worth of stock.

Accolade, Inc. Announces Changes to Its Board of Directors

Chairman of the Board & CEO recently bought US$177k worth of stock

Accolade, Inc. Appoints Kelli Burns as Senior Vice President, Chief Information Security Officer

Recent updates

Accolade, Inc. to Report Q2, 2024 Results on Oct 04, 2023

Accolade Expands Physician-Executive Leadership to Enhance Care Delivery and Improve the Healthcare Experience

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Accolade, Inc., Annual General Meeting, Aug 08, 2023

Accolade, Inc. to Report Q1, 2024 Results on Jun 29, 2023

Why Investors Shouldn't Be Surprised By Accolade, Inc.'s (NASDAQ:ACCD) 27% Share Price Surge

Chairman of the Board & CEO exercised options to buy US$4.3m worth of stock.

Is There Now An Opportunity In Accolade, Inc. (NASDAQ:ACCD)?

Price target increased by 8.9% to US$15.53

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Now 30% undervalued

Price target increased by 8.1% to US$14.27

Accolade, Inc. Announces Changes to Its Board of Directors

An Intrinsic Calculation For Accolade, Inc. (NASDAQ:ACCD) Suggests It's 28% Undervalued

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Accolade, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ending February 28, 2023; Provides Earnings Guidance for the Year Ending February 29, 2024

Accolade, Inc. to Report Q3, 2023 Results on Jan 09, 2023

Price target increased to US$13.93

Accolade: Inching Closer To Profitability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Accolade, Inc. Provides Revenue Guidance for the Fiscal Third Quarter Ending November 30, 2022 and Fiscal Year Ending February 28, 2023

Accolade Q2 2023 Earnings Preview

Accolade, Inc. to Report Q2, 2023 Results on Oct 06, 2022

Price target increased to US$11.58

Accolade: Fair And Reasonably Priced, But Needs More Time

Chairman of the Board & CEO recently bought US$177k worth of stock

Accolade, Inc. Appoints Kelli Burns as Senior Vice President, Chief Information Security Officer

Accolade, Inc. Provides Earnings Guidance for Second Quarter Ending August 31, 2022 and Fiscal Year Ending February 28, 2023

Accolade Q1 2023 Earnings Preview

Accolade, Inc.(NasdaqGS:ACCD) dropped from Russell 2000 Growth Index

Accolade, Inc., Annual General Meeting, Jul 26, 2022

Accolade, Inc. to Report Q1, 2023 Results on Jun 30, 2022

Accolade, Inc. announced delayed annual 10-K filing

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased to US$31.86

Accolade, Inc. to Report Q4, 2022 Results on Apr 28, 2022

Price target decreased to US$31.86

Accolade: Little Recent Applause

Price target decreased to US$33.92

Price target decreased to US$37.77

Consensus forecasts updated

Accolade, Inc. Provides Earnings Guidance for the Fourth Quarter, Fiscal Year Ending February 28, 2022 and Fiscal Year 2023

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$41.27

Price target decreased to US$49.73

Accolade Impresses With Revenue Growth But Faces Operating Losses

Accolade: I May Add To My Position

Second quarter 2022 earnings released: US$0.97 loss per share (vs US$0.47 loss in 2Q 2021)

Price target decreased to US$56.36

Accolade Introduces Personalized Healthcare Category

High number of new directors

Consensus forecasts updated

Accolade, Inc. (NASDAQ:ACCD) Just Reported And Analysts Have Been Lifting Their Price Targets

First quarter 2022 earnings released: US$0.84 loss per share (vs US$1.86 loss in 1Q 2021)

Price target increased to US$63.56

Accolade, Inc.(NasdaqGS:ACCD) dropped from Russell 2500 Value Index

Accolade, Inc. (NasdaqGS:ACCD) completed the acquisition of PlushCare, Inc.

Accolade, Inc. (NasdaqGS:ACCD) completed the acquisition of PlushCare, Inc.

Independent Chairman J. Cline has left the company

Independent Director William Frist has left the company

Full year 2021 earnings released: US$1.73 loss per share (vs US$9.13 loss in FY 2020)

Accolade, Inc. Provides Earnings Guidance for the First Quarter Ending May 31, 2021 and Fiscal Year Ending February 28, 2022

Accolade, Inc. 2021 Q4 - Results - Earnings Call Presentation

Consensus forecasts updated

Consensus EPS estimates increase to -US$1.31

Accolade, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Fiscal Year Ended February 28, 2021

Here's Why We're Not Too Worried About Accolade's (NASDAQ:ACCD) Cash Burn Situation

New 90-day low: US$39.07

Independent Director has left the company